Bernard B F, Krenning E P, Breeman W A, Rolleman E J, Bakker W H, Visser T J, Mäcke H, de Jong M
Department of Nuclear Medicine, Erasmus Medical University and Academic Hospital Dijkzigt, Rotterdam, The Netherlands.
J Nucl Med. 1997 Dec;38(12):1929-33.
Indium-111-DTPA-octreotide (111In-DTPAOC) is used successfully for imaging somatostatin receptor-positive lesions. A new and promising application is its use in peptide-receptor radionuclide therapy (PRRT). For the latter purpose, [DOTA0,D-Phe1,Tyr3]octreotide (DOTATOC), which is suitable for stable radiolabeling with 90Y, is probably even more promising. Significant renal uptake of these octreotide analogs exists, however, reducing the scintigraphic sensitivity for detection of small tumors in the perirenal region and limiting the possibilities for PRRT. We showed that the renal uptake of 111In-DTPAOC could be reduced to about 50% of control by L-lysine administration in vivo in rats. This study compares the effects of several doses and different methods of administration of D- and L-lysine, in addition to time-related effects of D-lysine, on kidney uptake of 111In-DTPAOC and 90Y-DOTATOC.
Male Wistar rats (200-250 g) were given 111In-DTPAOC (0.2 MBq, 0.5 microg-0.5 mg intravenously, intraperitoneally or orally) in the presence or absence of D- or L-lysine. At 1, 4 or 24 hr, the rats were killed, and the organs were isolated and counted for radioactivity. In different experiments, male Wistar rats (200-250 g) were given 90Y-DOTATOC (1 MBq, 0.5 microg intravenously) in the presence or absence of D-lysine. At 24 hr, the rats were killed, and the organs were isolated and counted for radioactivity.
Administration of D- or L-lysine in a single intravenous dose of 400 mg/kg, resulted in more than 50% inhibition of kidney uptake of 111In-DTPAOC at all time points tested, independently of the mass of 111In-DTPAOC used. Higher or repeated doses of lysine did not give a significantly higher percentage inhibition. D-lysine, given orally in a dose of 400 mg/kg at 30 or 15 min before 111In-DTPAOC injection, resulted in 30% and 20% inhibition of kidney uptake, respectively. L-lysine, given orally 30 min before 111In-DTPAOC administration, resulted in 30% inhibition as well. Inhibition of kidney uptake of 111In-DTPAOC by L-lysine after intraperitoneal administration was 40%. After L-lysine administration, 111In-DTPAOC was decreased in the kidneys and in somatostatin receptor-positive organs such as the pancreas and adrenal glands. In contrast, D-lysine did not have a significant effect on uptake in octreotide receptor-positive organs. Renal uptake of 90Y-DOTATOC was reduced by 65% by intravenous D-lysine, whereas radioactivity in blood, pancreas and adrenal glands was not affected.
D-lysine may be preferred to L-lysine for reduction of renal uptake of radioactivity during scintigraphy and PRRT because of its lower toxicity and because it should not interfere with the natural amino acid metabolic balance.
铟 - 111 - 二乙三胺五乙酸 - 奥曲肽(111In - DTPA - OC)已成功用于对生长抑素受体阳性病变进行成像。一种新的且有前景的应用是其在肽受体放射性核素治疗(PRRT)中的使用。对于后一用途,[DOTA0,D - Phe1,Tyr3]奥曲肽(DOTATOC)可能更具前景,它适用于与90Y进行稳定放射性标记。然而,这些奥曲肽类似物存在显著的肾脏摄取,这降低了肾周区域小肿瘤检测的闪烁显像敏感性,并限制了PRRT的可能性。我们表明,在大鼠体内给予L - 赖氨酸可将111In - DTPA - OC的肾脏摄取降低至对照的约50%。本研究比较了几种剂量和不同给药方法的D - 赖氨酸和L - 赖氨酸,以及D - 赖氨酸的时间相关效应,对111In - DTPA - OC和90Y - DOTATOC肾脏摄取的影响。
雄性Wistar大鼠(200 - 250 g)在有或无D - 或L - 赖氨酸存在的情况下,静脉内、腹腔内或口服给予111In - DTPA - OC(0.2 MBq,0.5 μg - 0.5 mg)。在1、4或24小时时,处死大鼠,分离器官并计数放射性。在不同实验中,雄性Wistar大鼠(200 - 250 g)在有或无D - 赖氨酸存在的情况下静脉内给予90Y - DOTATOC(1 MBq,0.5 μg)。在24小时时,处死大鼠,分离器官并计数放射性。
单次静脉注射400 mg/kg的D - 或L - 赖氨酸,在所有测试时间点均导致111In - DTPA - OC的肾脏摄取抑制超过50%,与所用111In - DTPA - OC的质量无关。更高剂量或重复剂量的赖氨酸并未产生显著更高的抑制百分比。在注射111In - DTPA - OC前30或15分钟口服400 mg/kg剂量的D - 赖氨酸,分别导致肾脏摄取抑制30%和20%。在111In - DTPA - OC给药前30分钟口服L - 赖氨酸,也导致30%的抑制。腹腔内给予L - 赖氨酸后,111In - DTPA - OC在肾脏以及生长抑素受体阳性器官如胰腺和肾上腺中的摄取降低40%。相比之下,D - 赖氨酸对奥曲肽受体阳性器官的摄取没有显著影响。静脉内给予D - 赖氨酸使90Y - DOTATOC的肾脏摄取降低65%,而血液、胰腺和肾上腺中的放射性不受影响。
在闪烁显像和PRRT期间,由于D - 赖氨酸毒性较低且不应干扰天然氨基酸代谢平衡,因此在降低放射性的肾脏摄取方面,D - 赖氨酸可能优于L - 赖氨酸。